Introduction {#Sec1}
============

Type 2 diabetes mellitus (T2DM) has become a global epidemic. The prevalence of diabetes in 2013 was 382 million people and is expected to increase to 592 million people by the year 2035 \[[@CR1]\]. While a myriad of glucose-lowering therapies are available, many patients with T2DM still do not reach treatment goals \[[@CR2]--[@CR4]\], exposing them to the risk of debilitating and costly complications. Joint guidelines from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) recommend a patient-centered, personalized approach for the treatment of diabetes, tailored to patients' individual needs and preferences along with considerations that include age, weight, comorbidities and complications, patient attitude, risk of hypoglycemia, disease duration, life expectancy, and available resources \[[@CR5]\]. Reliable, affordable, and convenient early markers used commonly in clinical practice and demonstrated to be predictive of long-term results may facilitate a personalized approach to therapy.

Early response to medication has been demonstrated to be a robust predictor of subsequent response to the medication across multiple therapeutic areas; in particular, lack of early response predicts lack of subsequent response. This early-response phenomenon has been observed in the treatment of schizophrenia with antipsychotics \[[@CR6]--[@CR10]\], bipolar disorder with antidepressants \[[@CR11]\], major depressive disorder with antidepressants \[[@CR12]\], attention-deficit/hyperactivity disorder with a selective norepinephrine reuptake inhibitor \[[@CR13], [@CR14]\], plaque psoriasis with monoclonal antibody therapy \[[@CR15]\], rheumatoid arthritis with monoclonal antibody therapy \[[@CR16]\], and breast cancer with neoadjuvant chemotherapy \[[@CR17]\]. Little is known about this early-response phenomenon in the treatment of diabetes. Accurate predictions of response to medication have notable implications for clinical improvements, treatment choices or transitions, and healthcare costs by helping clinicians make early treatment decisions for patients who are unlikely to be responsive to their current therapies and minimizing the time patients spend on suboptimal treatment regimens \[[@CR18]--[@CR22]\].

In T2DM, Karl et al. \[[@CR23]\] demonstrated that 6-month glycemic responses to insulin glargine can be predicted after 6--12 weeks of therapy---specifically, fasting plasma glucose \>180.2 mg/dL (10 mmol/L) after 6--12 weeks of insulin glargine therapy indicated that reaching a glycated hemoglobin (HbA~1c~) level target of ≤7.0% was unlikely---and thereby provided a means for predicting response to therapy early in the treatment approach; however, the predictive accuracy of this method was unclear. Given the limited understanding of early glycemic response to glucose-lowering medication, it is currently unclear whether early response to glucose-lowering medication is a robust predictor of subsequent response.

To help address this important information gap, this analysis assessed the predictive power of early response for subsequent response across 3 commonly prescribed glucose-lowering medications: metformin, sulfonylurea, and insulin glargine. We hypothesized that glycemic response at week 12 (early response) predicts subsequent glycemic responses at week 24 (the primary outcome) and week 52 (the secondary outcome) in the treatment of patients with T2DM.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

To evaluate the hypothesis for the 3 commonly prescribed glucose-lowering medications of metformin, sulfonylurea, and insulin glargine, 3 previously published, randomized clinical trials that included large samples with individual patient data were used for this study (Table [1](#Tab1){ref-type="table"}).Table 1Randomized clinical trials from which data were pooled for this analysisStudyTreatmentTrial sample sizeSample size used in this analysisDesignSchernthaner et al. \[[@CR24]\]Met^a^ vs. pio119959712-week titration\
40-week maintenanceCharbonnel et al. \[[@CR25]\]SU^a^ vs. pio127062616-week titration\
36-week maintenanceBuse et al. \[[@CR26]\]Glargine^a^ vs. lispro20911046OADs\
6-month initiation phase\
If HbA~1c~ ≤7.0%, then 24-month maintenance*Glargine* insulin glargine, *Lispro* insulin lispro, *Met* metformin, *OAD* oral anti-hyperglycemic medication, *Pio* pioglitazone, *SU* sulfonylurea, *HbA* ~*1c*~ glycated hemoglobin^a^Treatment arm included in present analysis

Metformin data (*n* = 597) were obtained from a trial that compared the glycemic control of metformin and pioglitazone in 1199 randomized, glucose-lowering drug-naive patients with poorly controlled T2DM over 52 weeks \[[@CR24]\].

Sulfonylurea data (*n* = 626) were obtained from a trial that compared the glycemic control of the sulfonylurea gliclazide and the thiazolidinedione pioglitazone in 1270 randomized, drug-naive patients with poorly controlled T2DM over 52 weeks \[[@CR25]\].

Insulin glargine data (*n* = 1046) were obtained from a trial that compared the durability of glycemic control of once-daily insulin glargine and twice-daily insulin lispro during a 6-month initiation phase in 2091 randomized patients with T2DM on oral glucose-lowering medications \[[@CR26]\]. Patients with HbA~1c~ levels of ≤7.0% at the end of the initiation phase continued in a maintenance phase for up to 24 months. Because only selected patients were monitored during the 24-month maintenance phase, the trial design did not permit 52-week follow-up for insulin glargine data in the current analysis.

Glycemic control for each of the 3 trials is shown in Table [2](#Tab2){ref-type="table"}. Data from patients with non-missing HbA~1c~ level values at baseline and weeks 12, 24, and 52 from the aforementioned clinical trials were analyzed. Treatment success at week 24 (the primary outcome) and week 52 (the secondary outcome) was assessed for each patient and defined as an HbA~1c~ level reduction of ≥1.0% or an HbA~1c~ level of \<7.0%. Thus, a patient needed to meet 1 of the 2 success criteria by reaching either an HbA~1c~ reduction of ≥1.0% or an HbA~1c~ level of \<7.0% to be considered having achieved treatment success.Table 2Glycemic controlMeasureTime pointMet (*N* = 597)SU (*N* = 626)Glargine (*N* = 1046)HbA~1c~ (%)Baseline8.7 (1.0)8.7 (1.1)8.9 (1.3)Week 127.5 (1.1)7.2 (1.1)7.6 (1.1)Week 247.1 (1.0)7.0 (1.1)7.4 (1.2)Week 527.2 (1.1)7.3 (1.2)NAHbA~1c~ change^a^ (%)Week 12−1.1 (1.0)−1.5 (1.0)−1.4 (1.2)Week 24−1.6 (1.2)−1.7 (1.1)−1.5 (1.3)Week 52−1.5 (1.2)−1.3 (1.1)NAFBG (mmol/L)Baseline11.3 (2.8)11.2 (2.9)10.1 (4.0)Week 129.0 (2.4)8.5 (2.4)7.2 (3.0)Week 248.7 (2.3)8.4 (2.4)7.0 (2.7)Week 529.1 (2.5)9.3 (3.0)NAFBG change^a^ (mmol/L)Week 12−2.2 (2.5)−2.7 (2.7)−2.9 (3.5)Week 24−2.5 (2.7)−2.8 (2.8)−3.2 (3.7)Week 52−2.1 (2.9)−2.0 (2.9)NAMean (standard deviation) shown*FBG* fasting blood glucose measure, *Glargine* insulin glargine, *Met* metformin, *NA* not applicable, *SU* sulfonylurea, *HbA* ~*1c*~ glycated hemoglobin^a^Change from baseline

The use of an HbA~1c~ level reduction of ≥1.0% as the threshold value in this analysis was selected because of its clinical relevance in diabetes management. The UK Prospective Diabetes Study showed that every 1.0% reduction in mean HbA~1c~ level was associated with reductions of 21% for any diabetes-related endpoint, 21% for diabetes-related deaths, 14% for myocardial infarctions, and 37% for microvascular complications \[[@CR27]\]. Further, the National Institute for Health and Care Excellence guideline selected an HbA~1c~ level reduction of ≥1.0% with the use of glucagon-like peptide-1 receptor agonists as a threshold criterion for continuing therapy \[[@CR28], [@CR29]\]. The use of an HbA~1c~ level of \<7.0% was selected because it is consistent with the ADA recommended HbA~1c~ target value \[[@CR30]\].

Gradient Boosting Method {#Sec4}
------------------------

The gradient boosting method was applied to the dataset from each trial to identify the optimal early-response variable, defined as the variable with the largest relative inference among the candidate variables for subsequent response prediction \[[@CR31]\]. Candidate early-response variables were based on HbA~1c~ levels at week 12 of \<7.4%, \<7.3%, \<7.2%, ..., \<6.6%; a reduction in HbA~1c~ level of ≥1.3%, ≥1.2%, ≥1.1%, ..., ≥0.5%; fasting blood glucose (FBG) levels at week 12 of \<12.5, \<12.0, \<11.5, ..., \<8.5 mmol/L; and a reduction in FBG level of ≥4.5, ≥4.0, ≥3.5, ..., ≥0.5 mmol/L.

Predictive parameters included sensitivity, which is the percentage of subsequent responders correctly identified; specificity, the percentage of subsequent non-responders correctly identified; positive predictive value (PPV), the percentage of subsequent responders among early responders; and negative predictive value (NPV), the percentage of subsequent non-responders among early non-responders (Table [3](#Tab3){ref-type="table"}).Table 3Sensitivity and specificityEarly-response treatment successSubsequent response treatment successYesNoYesABTrue positiveFalse positive^a^NoCDFalse negative^b^True negativePositive predictive value (PPV) = A/(A + B)Negative predictive value (NPV) = D/(C + D)^a^False positive results indicate the specificity of the analysis \[[@CR38]\]. Few false positive results denote high specificity. Specificity = D/(B + D)^b^False negative results indicate the sensitivity of the analysis. Few false negative results denote high sensitivity. Sensitivity = A/(A + C)

Correlation Coefficients {#Sec5}
------------------------

Correlation coefficients for HbA~1c~ level and HbA~1c~ level change were assessed using the Pearson product-moment correlation method \[[@CR32]\]. The analysis was conducted in SAS 9.0 (SAS Institute Inc., Cary, NC, USA).

Results {#Sec6}
=======

Patient Disposition and Demographics {#Sec7}
------------------------------------

Data from 2269 patients were included in this analysis (Table [1](#Tab1){ref-type="table"}). For metformin, sulfonylurea, and insulin glargine, 79%, 83%, and 85% of patients with available HbA~1c~ data at baseline were assessed at week 12 and week 24 (Table [4](#Tab4){ref-type="table"}). For metformin and sulfonylurea, 72% and 75% of patients also had HbA~1c~ assessed at week 52.Table 4Sample sizes for analysis populations, demographics, and patient characteristics as baselinePatient sampleMet (*N* = 597)SU (*N* = 626)Glargine (*N* = 1046)Patients with non-missing HbA~1c~ at baseline, week 12, and week 24470 (79%)517 (83%)886 (85%)Patients with non-missing HbA~1c~ at baseline, week 12, week 24, and week 52432 (72%)465 (74%)NACharacteristic Age (years)56 ± 956 ± 1057 ± 10 Male (%)345 (58%)386 (62%)552 (53%) Weight (kg)90 ± 1788 ± 1788 ± 21 BMI (kg/m^2^)31 ± 531 ± 532 ± 6 Duration of diabetes (years)3.0 ± 3.73.0 ± 3.89.3 ± 5.9 HbA~1c~ (%)8.7 ± 1.08.7 ± 1.19.0 ± 1.2 FBG (mmol/L)11.3 ± 2.811.2 ± 2.910.9 ± 3.1Mean ± standard deviation or *n* (%) are shown*BMI* body mass index, *FBG* fasting blood glucose, *Glargine* insulin glargine, *Met* metformin, *SU* sulfonylurea, *HbA* ~*1c*~ glycated hemoglobin

Across studies, the mean age was 56 or 57 years, the mean body weight was 88 or 90 kg, the mean body mass index was 31 or 32 kg/m^2^, and the mean HbA~1c~ level was 8.7% or 9.0% (Table [4](#Tab4){ref-type="table"}). The percentage of male patients ranged from 53% to 62%, and the mean FBG level ranged from 10.9 to 11.3 mmol/L. The mean duration of diabetes was 3.0 years for patients treated with metformin and sulfonylurea and 9.3 years for patients treated with insulin glargine.

Predictive Parameters {#Sec8}
---------------------

The optimal early-response variables identified by the GBM for metformin were a reduction in HbA~1c~ level of ≥0.8% at week 24 and a reduction in HbA~1c~ level of ≥0.6% at week 52. The optimal early-response variable for sulfonylurea was a reduction in HbA~1c~ level of ≥1.0% at both week 24 and week 52, and that for insulin glargine was a reduction in HbA~1c~ level of ≥1.0% at week 24. Thus, for each medication, the optimal early-response variable was equal or close to a reduction in HbA~1c~ level of ≥1.0%, which is considered to be clinically meaningful. Therefore, we chose a single, unified early-response measure (a reduction in HbA~1c~ level of ≥1.0%) for all 3 medications.

The GBM did not select an HbA~1c~ level of \<7.0% as an optimal early-response variable in any case. However, since an HbA~1c~ level of \<7.0% is clinically meaningful, it was combined with a reduction in HbA~1c~ of ≥1.0% for a composite unified measure in assessing predictive parameters (reduction in HbA~1c~ level of ≥1.0% or HbA~1c~ level of \<7.0%).

The predictive parameters for improvements in HbA~1c~ at week 24 and week 52, based on the composite unified early-response measure (reduction in HbA~1c~ level of ≥1.0% or HbA~1c~ level of \<7.0%) for metformin were 0.83, 0.81, 0.44, and 0.96; for sulfonylurea, 0.79, 0.94, 0.71, and 0.96; and for insulin glargine, 0.67, 0.89, 0.65, and 0.90. The predictive parameters for improvements in HbA~1c~ at week 52 for metformin were 0.73, 0.84, 0.56, and 0.92 and for sulfonylurea 0.45, 0.94, 0.74, and 0.82 (Table [5](#Tab5){ref-type="table"}).Table 5Predictive parameters for improvements in HbA~1c~ at 24 and 52 weeks based on HbA~1c~ levels at 12 weeksEarly-response measureSubsequent responseAgentSensitivitySpecificityPPVNPVComposite unified24 weeksMet0.830.810.440.96SU0.790.940.710.96Glargine0.670.890.650.9052 weeksMet0.730.840.560.92SU0.450.940.740.82Unified24 weeksMet0.900.740.380.98SU0.850.880.570.97Glargine0.740.830.560.9252 weeksMet0.820.780.500.94SU0.520.880.620.83Optimal24 weeksMet0.820.810.440.96SU0.850.880.570.97Glargine0.740.830.560.9252 weeksMet0.560.920.670.88SU0.520.880.620.83Composite unified early-response measure: HbA~1c~ reduction of ≥1.0% or HbA~1c~ level of \<7.0% at week 12; unified early-response measure: HbA~1c~ reduction of ≥1.0%; optimal early-response measure: HbA~1c~ reduction of ≥1.0% for sulfonylurea and glargine at week 24 and at week 52, HbA~1c~ reduction of ≥0.8% for metformin at week 24, and HbA~1c~ reduction of ≥0.6% for metformin at week 52*Glargine* insulin glargine, *Met* metformin, *NPV* negative predictive value, *PPV* positive predictive value, *SU* sulfonylurea, *HbA* ~*1c*~ glycated hemoglobin

The predictive parameters assessed using the optimal early-response measure and the unified measure were consistent with those of the composite unified measure and are shown in Table [5](#Tab5){ref-type="table"}. Across all therapies and early-response measures and at both time points, the NPV remained consistently high (range 0.82--0.98) (Table [5](#Tab5){ref-type="table"}).

Correlation Coefficients {#Sec9}
------------------------

In the 3 studies, high correlation coefficients were observed at week 12 vs. week 24 and at week 12 vs. week 52 for HbA~1c~ level and change from baseline (Table [6](#Tab6){ref-type="table"}). For HbA~1c~ level, the ranges for these correlation coefficients were 0.76--0.87 at week 12 vs. week 24 and 0.72--0.73 at week 12 vs. week 52. For HbA~1c~ change, the ranges were 0.84--0.89 at week 12 vs. week 24 and 0.76--0.80 at week 12 vs. week 52.Table 6Correlation coefficientsMeasureTime points (weeks)MetSUGlargineHbA~1c~12 vs. 240.790.870.7612 vs. 520.720.73NAHbA~1c~ change12 vs. 240.850.890.8412 vs. 520.800.76NA*Glargine* insulin glargine, *Met* metformin, *NA* not applicable, *SU* sulfonylurea, *HbA* ~*1c*~ glycated hemoglobin

Discussion {#Sec10}
==========

In this analysis of data from 3 clinical trials including 3 different glucose-lowering therapies, we demonstrated that lack of early glycemic response at week 12 is a reliable predictor of failure to achieve glycemic treatment targets (HbA~1c~ \<7.0% or HbA~1c~ reduction of ≥1.0%) at week 24 and week 52. NPV is consistently high for all 3 early-response measures (i.e., unified composite, unified, and optimal), which indicates that the chances are 82--98% that a patient who lacks early response to a specific treatment regimen at week 12 will be unable to achieve treatment targets when continuing that regimen. The high correlation coefficients observed at week 12 vs. week 24 and week 12 vs. week 52 corroborate the effectiveness of week-12 HbA~1c~ level and its change from baseline as predictors for long-term response.

Predicting the lack of early glycemic response was demonstrated using a clinically meaningful unified composite measure, which included a relative (HbA~1c~ reduction of ≥1.0%) and an absolute (HbA~1c~ \<7.0%) measure of glycemic control. The choice of a composite measure may minimize the impact of baseline HbA~1c~ in predicting treatment responses. For example, if a patient has a baseline HbA~1c~ level of 11% and a 24-week HbA~1c~ level of 7.5%, the patient would be considered a responder because of the clinically meaningful HbA~1c~ reduction of 3.5%. Thus, using a composite measure of response is likely to be applicable and relevant to more patients than using either the absolute or the relative measure alone. Additional information, such as demographic variables other than HbA~1c~, may further improve the NPV or PPV or improve the applicability of this approach to other or more specialized patient groups.

Among the prediction parameters (sensitivity, specificity, PPV, and NPV), NPV appears to be the most relevant parameter in clinical practice because clinicians need to identify patients who do not respond optimally to current medications or patients who are unlikely to respond with continued use of the medications. Clinicians' early evaluations may help identify the potential reasons a patient failed to respond to treatment and rule out the possibility that lack of response was driven by poor patient adherence to the prescribed regimen. Thus, the availability of such early information may be used as a tool for clinicians to help identify---shortly after medication initiation---patients who require a change in the current medication regimen in the form of an increased dose, a medication switch, an augmentation with another medication, or possibly the discontinuation of the medication for a period of time to better evaluate potential underlying causes of the observed poor response to therapy. The use of early treatment information may help optimize patients' treatment outcomes by minimizing the duration of suboptimal therapy while increasing the likelihood of relevant and timely change in the medication regimen, which may also help minimize waste of resources for patients and third-party healthcare payers alike.

The increasing prevalence of T2DM increases the economic burden of diabetes care, highlighting the need for improved methods of diabetes management. Overall, poor glycemic control, along with associated comorbidities, contributes to increased resource use and costs of diabetes care \[[@CR22], [@CR33]\]. Most patients with T2DM do not maintain glycemic goals in routine clinical practice \[[@CR2]--[@CR4]\]. Many patients with T2DM may not initiate or escalate treatment approaches sufficiently early in the course of the disease to reach recommended treatment targets \[[@CR19]--[@CR21], [@CR34], [@CR35]\], which contributes to poor glycemic control and ultimately to increased costs. Thus, improved methods for early effective management of T2DM and associated complications are necessary, including methods for early treatment decisions.

The ADA and EASD advocate for personalized, patient-centered treatment of T2DM \[[@CR5]\]. By design, recommended treatment paradigms are based on clinical trial results that involve a highly selected patient population and an artificial clinical environment \[[@CR5]\]. However, personalized care depends on responsiveness to the needs of individual patients \[[@CR36]\]. Predictive parameters of glycemic control, particularly NPV, may aid in personalizing patient therapy by providing a means of adapting broad, evidence-based treatment advice to individual therapeutic responses and promoting appropriate treatment regimens early in the management of diabetes.

Current findings need to be evaluated in the context of this study's limitations. We relied on data from randomized, controlled trials. Patient populations in controlled trials are highly selected; therefore, real-world results will be required to replicate the current findings, which are based on randomized clinical trials. This study defined treatment response only in terms of glycemic control, but other important treatment targets such as weight gain, hypoglycemia events, and microvascular and macrovascular complications are also critical in the management of T2DM. It would be prudent, therefore, for future research to use a composite measure that incorporates glycemic control with other treatment goals. The concept of threshold-based targets may deviate in part from the concept of individualized therapy; therefore, the definition of "responder" in this analysis may need to be further refined to include individual patient characteristics. In addition, although T2DM is a chronic illness, the current analysis focused on the first 24 and 52 weeks of therapy. Finally, this analysis focused on early response to 3 common medications in the treatment of T2DM, and additional research will be needed to assess the early-response phenomenon with various treatment regimens, especially combination therapy.

The strengths of this study include robust predictive parameters across a range of commonly prescribed glucose-lowering medications. The GBM algorithm is a highly robust statistical method without parametric model assumptions \[[@CR37]\]. This study used relatively large sample sizes from randomized trials, which would help minimize the bias of known or unknown confounders.

Conclusion {#Sec11}
==========

The high predictive values identified in this analysis support that lack of early glycemic response is a reliable clinical marker for identifying a lack of treatment success at 24 and 52 weeks. The high NPV (lack of early glycemic response) appears to be an effective indicator of the likely need for a change in (or intensification of) therapy and could become valuable in clinical practice. Moreover, study findings support the current treatment recommendations for T2DM, which advise clinicians to evaluate therapeutic response to pharmacologic interventions with metformin, sulfonylureas, or insulin glargine as early as 12 weeks.
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